Video

Sonja Althammer on Role of CD8 and PD-L1 Biomarkers for Immunotherapy in NSCLC

​Sonja Althammer, PhD, Team Leader Bioinformatics at Definiens, Munich, Bavaria, Germany, discusses a study looking to define a subgroup of patients with non–small cell lung cancer (NSCLC) who respond well to treatment with the PD-L1 inhibitor durvalumab.

Sonja Althammer, PhD, Team Leader Bioinformatics at Definiens, Munich, Bavaria, Germany, discusses a study looking to define a subgroup of patients with non—small cell lung cancer (NSCLC) who respond well to treatment with the PD-L1 inhibitor durvalumab.

It was already known that PD-L1 by itself serves as biomarker to predict response to durvalumab. However, researchers hypothesized that both CD8+ and PD-L1+ cells were critical for patient response to immunotherapies.

The study determined that the combination of CD8+ and PD-L1+ both correlated with response and improved overall survival with durvalumab. An independent study is planned to validate these results.

Related Videos
John M. Burke, MD
Eunice S. Wang, MD
Rachel E. Rau, MD
Wade T. Iams, MD
Andrew Kuykendall, MD
Timothy S. Fenske, MD, MS
Dasom (Caroline) Lee, MD
Christina Poh, MD
Mikkael A. Sekeres, MD, discusses the results of combining luspatercept and lenalidomide in lower-risk, non–5q deletion myelodysplastic syndromes.